AngioDynamics (ANGO) 10-Q 8 Apr 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Feb. 29, 2020	Apr. 06, 2020
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001275187
Current Fiscal Year End Date	--05-31
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Feb. 29, 2020
Document Transition Report	false
Entity File Number	0-50761
Entity Registrant Name	AngioDynamics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3146460
Entity Address, Address Line One	14 Plaza Drive
Entity Address, City or Town	Latham
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	12110
City Area Code	518
Local Phone Number	795-1400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,694,757
Common Stock
Title of 12(b) Security	Common stock, par value $.01
Trading Symbol	ANGO
Security Exchange Name	NASDAQ
Preferred Stock Purchase Rights
No Trading Symbol Flag	true
Title of 12(b) Security	Preferred Stock Purchase Rights
Security Exchange Name	NASDAQ

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	9 Months Ended
	Feb. 29, 2020
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements: Recently Issued Accounting Pronouncements - Adopted Standard Description Date Adopted Effect on the Consolidated Financial Statements ASU 2016-02, Leases (Topic 842) This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. June 1, 2019 Refer to Note 14, Leases, for the required disclosures related to adopting this standard. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2018-13, Fair Value Measurement (Topic 820) This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes. June 1, 2020 The Company is currently assessing the impact of this standard on the consolidated financial statements. ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. June 1, 2020 The Company is currently assessing the impact of this standard on the consolidated financial statements.

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019
Income Statement [Abstract]
Net sales	$ 69,780	$ 65,524	$ 205,825	$ 199,451
Cost of sales (exclusive of intangible amortization)	29,481	27,361	85,765	84,783
Gross profit	40,299	38,163	120,060	114,668
Operating expenses:
Research and development	8,395	6,915	22,450	21,365
Sales and marketing	20,934	18,385	60,427	56,054
General and administrative	10,203	8,718	29,651	26,414
Amortization of intangibles	5,019	4,660	13,417	12,599
Change in fair value of contingent consideration	419	609	116	865
Acquisition, restructuring and other items, net	1,565	2,550	4,486	9,700
Total operating expenses	46,535	41,837	130,547	126,997
Operating loss	(6,236)	(3,674)	(10,487)	(12,329)
Other (expenses) income:
Interest expense, net	(166)	(1,442)	(672)	(3,689)
Other expense, net	(131)	(266)	(67)	(72)
Total other expense, net	(297)	(1,708)	(739)	(3,761)
Loss from continuing operations before income tax benefit	(6,533)	(5,382)	(11,226)	(16,090)
Income tax benefit	(824)	(773)	(1,506)	(2,191)
Net loss from continuing operations		(4,609)	(9,720)	(13,899)
Income from discontinued operations, net of income tax	0	5,405	0	16,366
Net income (loss)	$ (5,709)	$ 796	$ (9,720)	$ 2,467
Loss per share continuing operations - basic (usd per share)	$ (0.15)	$ (0.12)	$ (0.26)	$ (0.37)
Loss per share continuing operations - diluted (usd per share)	(0.15)	(0.12)	(0.26)	(0.37)
Income per share discontinued operations - basic (usd per share)	0	0.14	0	0.44
Income per share discontinued operations - diluted (usd per share)	0	0.14	0	0.44
Income (loss) per share
Basic (in usd per share)	(0.15)	0.02	(0.26)	0.07
Diluted (in usd per share)	$ (0.15)	$ 0.02	$ (0.26)	$ 0.07
Basic weighted average shares outstanding (in shares)	37,999	37,518	37,924	37,446
Diluted weighted average shares outstanding (in shares)	37,999	37,518	37,924	37,446

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (5,709)	$ 796	$ (9,720)	$ 2,467
Other comprehensive income (loss), before tax:
Unrealized gain on marketable securities	0	0	0	33
Foreign currency translation	8	173	88	(158)
Other comprehensive income (loss), before tax	8	173	88	(125)
Income tax expense related to items of other comprehensive income	0	0	0	0
Other comprehensive income (loss), net of tax	8	173	88	(125)
Total comprehensive income (loss), net of tax	$ (5,701)	$ 969	$ (9,632)	$ 2,342

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Feb. 29, 2020	May 31, 2019
Current assets
Cash and cash equivalents	$ 27,160	$ 227,641
Accounts receivable, net of allowances of $1,991 and $1,906 respectively	35,619	43,577
Inventories	54,898	40,071
Prepaid expenses and other	11,369	4,003
Total current assets	129,046	315,292
Property, plant and equipment, net	28,182	24,258
Other assets	13,684	3,835
Intangible assets, net	201,956	145,387
Goodwill	359,093	347,666
Total assets	731,961	836,438
Current liabilities
Accounts payable	18,304	22,829
Accrued liabilities	27,445	38,338
Current portion of long-term debt	0	7,500
Current portion of contingent consideration	889	4,635
Other current liabilities	2,074	0
Total current liabilities	48,712	73,302
Long-term debt, net of current portion	14,341	124,407
Contingent consideration, net of current portion	26,405	8,851
Deferred income taxes	24,013	14,542
Other long-term liabilities	8,015	521
Total liabilities	121,486	221,623
Commitments and contingencies (Note 15)
Stockholders' equity
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $.01 per share, 75,000,000 shares authorized; 38,434,757 and 37,984,382 shares issued and 38,064,757 and 37,614,382 shares outstanding at February 29, 2020 and May 31, 2019, respectively	374	372
Additional paid-in capital	560,330	555,040
Retained earnings	56,749	66,469
Treasury stock, 370,000 shares at February 29, 2020 and May 31, 2019, respectively	(5,714)	(5,714)
Accumulated other comprehensive loss	(1,264)	(1,352)
Total Stockholders’ Equity	610,475	614,815
Total Liabilities and Stockholders' Equity	$ 731,961	$ 836,438

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Feb. 29, 2020	May 31, 2019
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 1,991	$ 1,906
Preferred stock, par value (in usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	38,434,757	37,984,382
Common stock, shares outstanding (in shares)	38,064,757	37,614,382
Treasury stock, shares (in shares)	370,000	370,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019
Cash flows from operating activities:
Net income (loss)	$ (9,720)	$ 2,467
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	17,550	19,158
Non-cash lease expense	1,567
Stock based compensation	5,998	7,119
Change in fair value of contingent consideration	116	865
Gain on contingent consideration for IPR&D Write-off	(1,606)	633
Change in accounts receivable allowances	186	(99)
Fixed and intangible asset impairments and disposals	395	689
Write-off of other assets	593	0
Other	70	(5)
Changes in operating assets and liabilities:
Accounts receivable	7,834	(3,853)
Inventories	(14,036)	(2,702)
Prepaid expenses and other	(9,378)	(1,508)
Accounts payable, accrued and other liabilities	(18,003)	(10,336)
Net cash (used in) provided by operating activities	(18,434)	12,428
Cash flows from investing activities:
Additions to property, plant and equipment	(5,756)	(2,303)
Acquisition of intangibles	(350)	0
Cash paid for acquisitions	(55,760)	(84,920)
Proceeds from sale of marketable securities	0	1,350
Net cash used in investing activities	(61,866)	(85,873)
Cash flows from financing activities:
Proceeds from issuance of and borrowings on long-term debt	15,000	55,000
Repayment of long-term debt	(132,500)	(13,750)
Deferred financing costs on long-term debt	775	0
Payment of acquisition related contingent consideration	(1,208)	(2,100)
Proceeds (outlays) from exercise of stock options and employee stock purchase plan	(706)	2,023
Net cash provided by (used in) financing activities	(120,189)	41,173
Effect of exchange rate changes on cash and cash equivalents	8	(120)
Decrease in cash and cash equivalents	(200,481)	(32,392)
Cash and cash equivalents at beginning of period	227,641	74,096
Cash and cash equivalents at end of period	27,160	41,704
Supplemental disclosure of non-cash investing and financing activities:
Accrual for capital expenditures incurred during the period	214	(42)
Fair value of contingent consideration for acquisitions	14,900	25,100
Fair value of acquisition consideration included in other long-term liabilities	$ 0	$ 4,691

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Restricted stock units	Performance share units	Common Stock	Common StockRestricted stock units	Common StockPerformance share units	Additional paid in capital	Additional paid in capitalRestricted stock units	Retained earnings	Accumulated other comprehensive loss	Treasury Stock
Beginning Balance, Shares at May. 31, 2018				37,594,493
Beginning Balance at May. 31, 2018	$ 542,595			$ 370			$ 543,762		$ 5,129	$ (952)	$ (5,714)
Beginning Balance,Treasury Shares at May. 31, 2018											(370,000)
Net income (loss)	(469)								(469)
Exercise of stock options, Shares				71,336
Exercise of stock options	608			$ 1			607
Issuance/Cancellation of performance share units and restricted stock units, net, Shares					149,446	5,235
Issuance/Cancellation of performance share units and restricted stock units		$ (460)	$ 0					$ (460)
Purchase of common stock under ESPP, Shares				40,547
Purchases of common stock under ESPP	557			$ 1			556
Stock-based compensation	2,150						2,150
Other comprehensive income, net of tax	(92)									(92)
Ending Balance, Shares at Aug. 31, 2018				37,861,057
Ending Balance at Aug. 31, 2018	544,889			$ 372			546,615		4,660	(1,044)	$ (5,714)
Ending Balance,Treasury Shares at Aug. 31, 2018											(370,000)
Beginning Balance, Shares at May. 31, 2018				37,594,493
Beginning Balance at May. 31, 2018	542,595			$ 370			543,762		5,129	(952)	$ (5,714)
Beginning Balance,Treasury Shares at May. 31, 2018											(370,000)
Net income (loss)	2,467
Ending Balance, Shares at Feb. 28, 2019				37,955,894
Ending Balance at Feb. 28, 2019	554,079			$ 372			552,902		7,596	(1,077)	$ (5,714)
Ending Balance,Treasury Shares at Feb. 28, 2019											(370,000)
Beginning Balance, Shares at Aug. 31, 2018				37,861,057
Beginning Balance at Aug. 31, 2018	544,889			$ 372			546,615		4,660	(1,044)	$ (5,714)
Beginning Balance,Treasury Shares at Aug. 31, 2018											(370,000)
Net income (loss)	2,140								2,140
Exercise of stock options, Shares				10,571
Exercise of stock options	149						149
Issuance/Cancellation of performance share units and restricted stock units, net, Shares					3,901
Issuance/Cancellation of performance share units and restricted stock units		0
Stock-based compensation	2,591						2,591
Other comprehensive income, net of tax	(206)									(206)
Ending Balance, Shares at Nov. 30, 2018				37,875,529
Ending Balance at Nov. 30, 2018	549,563			$ 372			549,355		6,800	(1,250)	$ (5,714)
Ending Balance,Treasury Shares at Nov. 30, 2018											(370,000)
Net income (loss)	796								796
Exercise of stock options, Shares				40,346
Exercise of stock options	603						603
Issuance/Cancellation of performance share units and restricted stock units, net, Shares					7,703
Issuance/Cancellation of performance share units and restricted stock units		(49)						(49)
Purchase of common stock under ESPP, Shares				32,316
Purchases of common stock under ESPP	615						615
Stock-based compensation	2,378						2,378
Other comprehensive income, net of tax	173									173
Ending Balance, Shares at Feb. 28, 2019				37,955,894
Ending Balance at Feb. 28, 2019	554,079			$ 372			552,902		7,596	(1,077)	$ (5,714)
Ending Balance,Treasury Shares at Feb. 28, 2019											(370,000)
Beginning Balance, Shares at May. 31, 2019				37,984,382
Beginning Balance at May. 31, 2019	$ 614,815			$ 372			555,040		66,469	(1,352)	$ (5,714)
Beginning Balance,Treasury Shares at May. 31, 2019	(370,000)										(370,000)
Net income (loss)	$ (1,275)								(1,275)
Exercise of stock options, Shares				48,136
Exercise of stock options	531			$ 1			530
Issuance/Cancellation of performance share units and restricted stock units, net, Shares					287,087
Issuance/Cancellation of performance share units and restricted stock units		(2,459)						(2,459)
Purchase of common stock under ESPP, Shares				40,270
Purchases of common stock under ESPP	628						628
Stock-based compensation	1,984						1,984
Other comprehensive income, net of tax	(151)									(151)
Ending Balance, Shares at Aug. 31, 2019				38,359,875
Ending Balance at Aug. 31, 2019	614,073			$ 373			555,723		65,194	(1,503)	$ (5,714)
Ending Balance,Treasury Shares at Aug. 31, 2019											(370,000)
Beginning Balance, Shares at May. 31, 2019				37,984,382
Beginning Balance at May. 31, 2019	$ 614,815			$ 372			555,040		66,469	(1,352)	$ (5,714)
Beginning Balance,Treasury Shares at May. 31, 2019	(370,000)										(370,000)
Net income (loss)	$ (9,720)
Ending Balance, Shares at Feb. 29, 2020				38,434,757
Ending Balance at Feb. 29, 2020	$ 610,475			$ 374			560,330		56,749	(1,264)	$ (5,714)
Ending Balance,Treasury Shares at Feb. 29, 2020	(370,000)										(370,000)
Beginning Balance, Shares at Aug. 31, 2019				38,359,875
Beginning Balance at Aug. 31, 2019	$ 614,073			$ 373			555,723		65,194	(1,503)	$ (5,714)
Beginning Balance,Treasury Shares at Aug. 31, 2019											(370,000)
Net income (loss)	(2,736)								(2,736)
Issuance/Cancellation of performance share units and restricted stock units, net, Shares					4,051
Issuance/Cancellation of performance share units and restricted stock units			$ 0
Stock-based compensation	2,242						2,242
Other comprehensive income, net of tax	231									231
Ending Balance, Shares at Nov. 30, 2019				38,363,926
Ending Balance at Nov. 30, 2019	613,810			$ 373			557,965		62,458	(1,272)	$ (5,714)
Ending Balance,Treasury Shares at Nov. 30, 2019											(370,000)
Net income (loss)	(5,709)								(5,709)
Exercise of stock options, Shares				2,500
Exercise of stock options	30						30
Issuance/Cancellation of performance share units and restricted stock units, net, Shares					8,034
Issuance/Cancellation of performance share units and restricted stock units		$ (25)						$ (25)
Purchase of common stock under ESPP, Shares				60,297
Purchases of common stock under ESPP	589			$ 1			588
Stock-based compensation	1,772						1,772
Other comprehensive income, net of tax	8									8
Ending Balance, Shares at Feb. 29, 2020				38,434,757
Ending Balance at Feb. 29, 2020	$ 610,475			$ 374			$ 560,330		$ 56,749	$ (1,264)	$ (5,714)
Ending Balance,Treasury Shares at Feb. 29, 2020	(370,000)										(370,000)

Consolidated Financial Statemen

Consolidated Financial Statements	9 Months Ended
	Feb. 29, 2020
Accounting Policies [Abstract]
Consolidated Financial Statements	CONSOLIDATED FINANCIAL STATEMENTS The Consolidated Balance Sheet as of February 29, 2020, the Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended February 29, 2020 and February 28, 2019, the Consolidated Statements of Stockholders’ Equity for the three months ended February 29, 2020 and February 28, 2019 and the Consolidated Statements of Cash Flows for the nine months ended February 29, 2020 and February 28, 2019 have been prepared by us and are unaudited. The Consolidated Balance Sheet as of May 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended February 29, 2020 (and for all periods presented) have been made. The unaudited interim consolidated financial statements for the three and nine months ended February 29, 2020 and February 28, 2019 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated. On May 31, 2019, the Company completed the sale of the Fluid Management business and all of the assets used primarily in connection with the Fluid Management business (Note 3). As the disposal of this business represents a strategic shift with a major effect on the Company's operations, for all periods presented in our Consolidated Statements of Operations and Comprehensive Loss, all sales, costs, expenses, gains and income taxes attributable to Fluid Management have been reported under the captions, “Income from Discontinued Operations, Net of Income Tax.” Cash flows used in or provided by Fluid Management have been reported in the Consolidated Statements of Cash Flows under operating and investing activities.

Acquisitions

Acquisitions	9 Months Ended
	Feb. 29, 2020
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS C3 Wave Tip Location Acquisition On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc. for an aggregate purchase price of $10.0 million with $5.0 million of potential future contingent consideration related to technical milestones. This acquisition fills a gap in the Vascular Access portfolio and supports the Company's strategic plan. The Company accounted for this acquisition as an asset purchase. The Company recorded the amount paid at closing as inventory of $0.6 million and intangible assets of a trademark of $0.9 million and product technology of $8.5 million. The intangible assets will be amortized over 15 years. The contingent consideration is comprised of technical milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable. Eximo Acquisition On October 2, 2019, the Company entered into a share purchase agreement to acquire Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm B Laser Atherectomy technology. The aggregate purchase price of $60.7 million included an upfront payment of $45.8 million and contingent consideration with an estimated fair value of $14.9 million. This acquisition expands and complements the Company’s Vascular Interventions and Therapies product portfolio by adding the 355nm B Laser Atherectomy technology which treats Peripheral Artery Disease. The Company accounted for the Eximo acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is non-deductible for income tax purposes. The Company has not disclosed the amount of revenue and earnings for sales of Eximo products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the Eximo acquisition, which are included in "acquisition, restructuring and other items, net" in the accompanying Consolidated Statements of Operations, were approximately $0.6 million in fiscal year 2020. The following table summarizes the preliminary aggregate purchase price allocated to the net assets acquired: (in thousands) Preliminary allocation Adjustments (1) Revised allocation Accounts receivable $ 50 $ — $ 50 Inventory 150 — 150 Prepaid and other current assets 54 — 54 Long-term deposits 51 51 Property, plant and equipment 397 — 397 Intangible assets: Product technology 59,000 1,300 60,300 Goodwill 12,428 (1,001) 11,427 Total assets acquired $ 72,130 $ 299 $ 72,429 Liabilities assumed Accounts payable $ 84 $ — $ 84 Other current liabilities 615 — 615 Deferred tax liabilities 10,771 299 11,070 Total liabilities assumed $ 11,470 $ 299 $ 11,769 Net assets acquired $ 60,660 $ — $ 60,660 (1) Measurement period adjustments are recognized on a prospective basis in the period of change, instead of restating prior periods. There was no impact to reported earnings in connection with these measurement period adjustments for the periods presented. Amounts represent adjustments to the preliminary purchase price allocation first presented in the Company's Quarterly Report on Form 10-Q for the quarter ended November 30, 2019 resulting from revising the Company's purchase price allocation for this acquisition. The allocation of the purchase price to the assets acquired and liabilities assumed, including the amount allocated to goodwill, is subject to change within the measurement period (up to one year from the acquisition date) as additional information that existed at the date of the acquisition related to the values of assets acquired and liabilities assumed is obtained. The value assigned to the product technology was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. The product technology is deemed to have a useful life of fifteen years and will be amortized on a straight-line basis over the useful life. The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations. RadiaDyne Acquisition On September 21, 2018, the Company acquired RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes. The aggregate purchase price of $75.0 million included an upfront payment of $47.9 million, contingent consideration with an estimated fair value of $22.3 million, an indemnification holdback of $4.6 million and a purchase price holdback of $0.2 million. The fair value of $22.3 million in contingent consideration comprises $16.5 million for the revenue milestones and $5.8 million for the technical milestones. The $4.6 million indemnification holdback is recorded in accrued liabilities at February 29, 2020 and the $0.2 million purchase price holdback was initially recorded in accrued liabilities, and was paid during the third quarter of fiscal year 2019. This acquisition expands the Company’s growing Oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies. The Company accounted for the RadiaDyne acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes. The Company has not disclosed the amount of revenue and earnings for sales of RadiaDyne products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the RadiaDyne acquisition, which are included in "acquisition, restructuring and other items, net" in the accompanying Consolidated Statements of Operations, were approximately $1.6 million in fiscal year 2019. The following table summarizes the preliminary and final aggregate purchase price allocated to the net assets acquired: (in thousands) Final allocation Accounts receivable $ 900 Inventory 732 Prepaid and other current assets 98 Property, plant and equipment 133 Intangible assets: RadiaDyne trademark 400 OARtrac trademark 200 RadiaDyne legacy product technology 1,500 OARtrac product technology 18,900 RadiaDyne customer relationships 4,600 Goodwill 47,982 Total assets acquired $ 75,445 Liabilities assumed Accounts payable $ 352 Accrued expenses 106 Total liabilities assumed $ 458 Net assets acquired $ 74,987 The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of FY19. The values assigned to the RadiaDyne and OARtrac trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademarks are deemed to have a useful life of five seven The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over fifteen years. The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations. BioSentry Acquisition On August 14, 2018, the Company acquired the BioSentry product from Surgical Specialties, LLC (“SSC”), for an aggregate purchase price of $39.8 million of which $37.0 million was paid on August 14, 2018 and $2.8 million was recorded as contingent consideration. The contingent consideration liability was recorded at fair value and was paid in the fourth quarter of fiscal year 2019 upon fulfillment of hydrogel orders by SSC. The Company accounted for the BioSentry acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes. The Company has not disclosed the amount of revenue and earnings for sales of BioSentry products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the BioSentry acquisition, which are included in "acquisition, restructuring and other items, net" in the accompanying Consolidated Statements of Operations, were approximately $1.0 million in fiscal year 2019. The following table summarizes the preliminary and revised final purchase price allocated to the net assets acquired: (in thousands) Final allocation Inventory $ 50 Property, plant and equipment 10 Intangible assets: BioSentry trademark 2,500 BioSentry product technology 20,900 Customer relationships 2,600 Goodwill 13,740 Net assets acquired $ 39,800 The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of FY19. The values assigned to the BioSentry trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademark and product technologies are deemed to have a fifteen The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over ten years.

Divestitures Divestitures

Divestitures Divestitures	9 Months Ended
	Feb. 29, 2020
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	DIVESTITURES Fluid Management On May 31, 2019, the Company completed the sale of the NAMIC Fluid Management business (the “Divestiture”) and all of the assets used primarily in connection with the Fluid Management business to Medline Industries, Inc. (“Medline”) pursuant to an asset purchase agreement dated April 17, 2019 (the “Asset Purchase Agreement”). Total consideration received by the Company for the Divestiture in the fourth quarter of fiscal year 2019 was $169.2 million in cash and resulted in a gain of $46.6 million after working capital adjustments of $0.6 million. The gain was recorded in discontinued operations. On June 3, 2019, a portion of the net proceeds were used to retire the outstanding balance on the Term Loan and Revolving Facility and the remaining net proceeds will continue to be invested in the business. Pursuant to a transition services agreement entered into and effective on the closing of the transaction, the Company will supply certain services to Medline. Medline will receive certain legal, human resource, tax, accounting and information technology services from the Company for a period generally not to exceed 24 months. As a result of the Divestiture, the results of operations from the Fluid Management business are reported in the accompanying Consolidated Statements of Operations as “Income from discontinued operations, net of income tax” for the three and nine months ended February 28, 2019. The following table summarizes the financial results of our discontinued operations: Three Months Ended Nine Months Ended (in thousands) Feb 28, 2019 Feb 28, 2019 Net sales $ 20,818 $ 63,733 Cost of sales (exclusive of amortization) 12,290 38,134 Gross profit 8,528 25,599 Operating expenses Research and development 295 870 Sales and marketing 1,028 3,061 General and administrative 62 198 Amortization of intangibles 682 2,047 Total operating expenses 2,067 6,176 Operating income 6,461 19,423 Income from discontinued operations before income taxes 6,461 19,423 Income tax expense 1,056 3,057 Income from discontinued operations $ 5,405 $ 16,366 In accordance with accounting principles generally accepted in the United States (“GAAP”), only expenses specifically identifiable and related to a business to be disposed may be allocated to discontinued operations. As such, the selling and marketing, research and development and general and administrative expenses recorded in discontinued operations include corporate costs incurred directly in support of the Fluid Management portfolio. Total operating and investing cash flows of discontinued operations for the nine months ended February 28, 2019 is comprised of the following, which excludes the effect of income taxes: Nine Months Ended (in thousands) Feb 28, 2019 Net cash provided by operating activities 841 Net cash provided by investing activities 759

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Feb. 29, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue Recognition Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company has one primary revenue stream which is the sales of its products. Disaggregation of Revenue The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the three and nine months ended February 29, 2020 and February 28, 2019: Three months ended Feb 29, 2020 Three months Ended Feb 28, 2019 (in thousands) United States International Total United States International Total Net sales Vascular Interventions & Therapies $ 26,788 $ 3,764 $ 30,552 $ 26,294 $ 3,004 $ 29,298 Vascular Access 20,018 4,624 24,642 18,952 3,396 $ 22,348 Oncology 8,083 6,503 14,586 8,154 5,724 $ 13,878 Total $ 54,889 $ 14,891 $ 69,780 $ 53,400 $ 12,124 $ 65,524 Nine months ended Feb 29, 2020 Nine months Ended Feb 28, 2019 (in thousands) United States International Total United States International Total Net sales Vascular Interventions & Therapies $ 80,065 $ 10,551 $ 90,616 $ 79,386 $ 9,484 $ 88,870 Vascular Access 57,865 12,720 70,585 59,480 10,381 69,861 Oncology 25,451 19,173 44,624 22,329 18,391 40,720 Total $ 163,381 $ 42,444 $ 205,825 $ 161,195 $ 38,256 $ 199,451 Net Product Revenue The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distribution partners and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. Contracts and Performance Obligations The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Transaction Price and Allocation to Performance Obligations Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method. As such, revenue is recorded net of rebates, returns and other deductions. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately. Revenue Recognition Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract. In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer. The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability. Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations. Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the nine months ended February 29, 2020, such product returns were not material. Contract Balances with Customers A receivable is recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets. The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers: (in thousands) Feb 29, 2020 May 31, 2019 Receivables $ 35,619 $ 43,577 Contract assets $ — $ — Contract liabilities $ 612 $ 681 During the nine months ended February 29, 2020, the Company recognized $1.6 million in revenue that was included in contract liabilities as of the beginning of the period. This was offset by additions to contract liabilities of $1.6 million in the first nine months of the year. Costs to Obtain or Fulfill a Customer Contract Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.

Inventories

Inventories	9 Months Ended
	Feb. 29, 2020
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following: (in thousands) Feb 29, 2020 May 31, 2019 Raw materials $ 21,304 $ 16,045 Work in process 9,385 6,786 Finished goods 24,209 17,240 Inventories $ 54,898 $ 40,071

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Feb. 29, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	GOODWILL AND INTANGIBLE ASSETS Intangible assets other than goodwill are amortized over their estimated useful lives on either a straight-line basis or proportionately to the benefit being realized. Useful lives range from two Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. The Company's annual testing for impairment of goodwill was completed as of December 31, 2019. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value as of December 31, 2019. Even though the Company determined that there was no goodwill impairment as of December 31, 2019, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2020. As a result of the current economic environment and the impact that the COVID-19 global pandemic has had on the global capital markets, the Company's market capitalization is below its reporting unit's carrying value as of February 29, 2020. The Company has concluded that this decline in market capitalization is temporary; however, the ultimate scope and scale that the COVID-19 global pandemic has on the Company may necessitate the Company testing goodwill for impairment in the fourth quarter. The changes in the carrying amount of goodwill for the nine months ended February 29, 2020 were as follows: (in thousands) Goodwill balance at May 31, 2019 $ 347,666 Addition for Eximo acquisition (Note 2) 11,427 Goodwill balance at February 29, 2020 $ 359,093 Intangible assets consisted of the following: Feb 29, 2020 (in thousands) Gross carrying value Accumulated Net carrying Product technologies $ 251,773 $ (85,105) $ 166,668 Customer relationships 60,149 (29,005) 31,144 Trademarks 10,150 (6,640) 3,510 Licenses 6,087 (5,453) 634 $ 328,159 $ (126,203) $ 201,956 May 31, 2019 (in thousands) Gross carrying value Accumulated Net carrying Product technologies $ 182,971 $ (75,412) $ 107,559 Customer relationships 60,166 (25,950) 34,216 Trademarks 9,300 (6,404) 2,896 Licenses 5,752 (5,036) 716 $ 258,189 $ (112,802) $ 145,387 Amortization expense for the three months ended February 29, 2020 and February 28, 2019 was $5.0 million and $4.7 million, respectively. Amortization expense for the nine months ended February 29, 2020 and February 28, 2019 was $13.4 million and $12.6 million, respectively. Expected future amortization expense related to the intangible assets is as follows: (in thousands) Remainder of 2020 $ 4,856 2021 18,607 2022 18,003 2023 17,941 2024 16,367 2025 and thereafter 126,182 $ 201,956

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Feb. 29, 2020
Payables and Accruals [Abstract]
Accrued Liabilities	ACCRUED LIABILITIES Accrued liabilities consisted of the following: (in thousands) Feb 29, 2020 May 31, 2019 Payroll and related expenses $ 11,159 $ 14,987 Royalties 2,015 2,088 Accrued severance 1,020 504 Sales and franchise taxes 631 807 Outside services 2,347 3,514 Litigation matters — 2,700 Indemnification holdback 4,986 4,807 Other 5,287 8,931 $ 27,445 $ 38,338

Long Term Debt

Long Term Debt	9 Months Ended
	Feb. 29, 2020
Debt Disclosure [Abstract]
Long Term Debt	LONG TERM DEBT On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and Bank of America, N.A. and KeyBank National Association, as co-syndication agents. The Credit Agreement provides for a $125.0 million secured revolving credit facility (the “Revolving Facility”), which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million. The proceeds may be used to refinance certain existing indebtedness of the Company and its subsidiaries, to finance the working capital needs, and for general corporate purposes (including permitted acquisitions), of the Company and its subsidiaries. The Credit Agreement has a five year maturity. Interest on the facility will be based, at the Company’s option, on a base rate of LIBOR plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. After default, the interest rate may be increased by 2.0%. The facility will also carry a commitment fee of 0.20% to 0.25% per annum on the unused portion. The Company's obligations under the Revolving Facility are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Revolving Facility are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows: • maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00). • fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00. * The definitions of consolidated total indebtedness and consolidated EBITDA are maintained in the credit agreement included as an exhibit to Form 8-k filed on June 6, 2019. As of February 29, 2020, there was $15.0 million outstanding balance on the Revolving Facility. As of February 29, 2020 and May 31, 2019, the carrying value of long-term debt approximated its fair market value. The interest rate on the Revolving Facility at February 29, 2020 was 2.92%. The Company was in compliance with the Credit Agreement covenants as of February 29, 2020. The Company's maturities of principal obligations under the Credit Agreement are as follows as of February 29, 2020: (in thousands) Revolving Facility (1) $ 15,000 Less: Unamortized debt issuance costs (659) Total $ 14,341 (1) The Revolving Facility is due in fiscal year 2024.

Income Taxes

Income Taxes	9 Months Ended
	Feb. 29, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur. The estimated annual effective tax rate prior to discrete items was 12.9% as of the third quarter of fiscal 2020, as compared to 14.0% for the same period in fiscal 2019. In fiscal 2020, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share based compensation). The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence that the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal 2016, except the naked credit deferred tax liability. Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of February 29, 2020. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Feb. 29, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION The Company has two stock-based compensation plans that provide for the issuance of up to approximately 11.3 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to the Company's employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to the Company's employees, directors and other service providers. The Company also has an employee stock purchase plan. For the three months ended February 29, 2020 and February 28, 2019, share-based compensation expense was $1.8 million and $2.4 million, respectively. For the nine months ended February 29, 2020 and February 28, 2019, share-based compensation expense was $6.0 million and $7.1 million, respectively. During the nine months ended February 29, 2020 and February 28, 2019, the Company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company's shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award. During the nine months ended February 29, 2020 and February 28, 2019, the Company granted performance share units under the 2004 Plan to certain employees. The awards may be earned by achieving relative performance levels over the year requisite service period. The performance criteria are based on achieving certain performance targets and the total shareholder return ("TSR") of the Company's common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards are based on the closing trading value of the Company's shares on the date of grant and use a Monte Carlo simulation model.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Feb. 29, 2020
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive. The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 29, 2020 and February 28, 2019 (in thousands): Three Months Ended Nine Months Ended (in thousands) Feb 29, 2020 Feb 28, 2019 Feb 29, 2020 Feb 28, 2019 Basic 37,999 37,518 37,924 37,446 Effect of dilutive securities — — — — Diluted 37,999 37,518 37,924 37,446 Securities excluded as their inclusion would be anti-dilutive 2,699 2,293 2,656 2,293

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Feb. 29, 2020
Segment Reporting [Abstract]
Segment and Geographic Information	SEGMENT AND GEOGRAPHIC INFORMATION The Company considers the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. The Company's chief operating decision maker, the President and Chief Executive Officer (CEO), evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources. The table below summarizes net sales by Global Business Unit: Three Months Ended Nine months ended (in thousands) Feb 29, 2020 Feb 28, 2019 Feb 29, 2020 Feb 28, 2019 Net sales Vascular Interventions & Therapies $ 30,552 $ 29,298 $ 90,616 $ 88,870 Vascular Access 24,642 22,348 70,585 69,861 Oncology 14,586 13,878 44,624 40,720 Total $ 69,780 $ 65,524 $ 205,825 $ 199,451 The table below presents net sales by geographic area based on external customer location: Three Months Ended Nine months ended (in thousands) Feb 29, 2020 Feb 28, 2019 Feb 29, 2020 Feb 28, 2019 Net sales United States $ 54,889 $ 53,400 $ 163,381 $ 161,195 International 14,891 12,124 42,444 38,256 Total $ 69,780 $ 65,524 $ 205,825 $ 199,451

Fair Value

Fair Value	9 Months Ended
	Feb. 29, 2020
Fair Value Disclosures [Abstract]
Fair Value	FAIR VALUE On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows: • Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. The Company's recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities. The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 29, 2020 and May 31, 2019: Fair Value Measurements using inputs considered as: Fair Value at Feb 29, 2020 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 27,294 $ 27,294 Total Financial Liabilities $ — $ — $ 27,294 $ 27,294 Fair Value Measurements using inputs considered as: Fair Value at May 31, 2019 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 13,486 $ 13,486 Total Financial Liabilities $ — $ — $ 13,486 $ 13,486 There were no transfers between Level 1, 2 and 3 for the three and nine months ended February 29, 2020. The table below presents the changes in fair value components of Level 3 instruments in the three and nine months ended February 29, 2020: Three Months Ended Feb 29, 2020 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, November 30, 2019 $ 26,875 Total gains or losses (realized/unrealized): Change in present value of contingent consideration (1) 419 Balance, February 29, 2020 $ 27,294 Nine Months Ended Feb 29, 2020 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, May 31, 2019 $ 13,486 Total gains or losses (realized/unrealized): Contingent consideration liability recorded as the result of the acquisitions (Note 2) 14,900 Change in present value of contingent consideration (1) 116 Contingent consideration payments (1,208) Balance, February 29, 2020 $ 27,294 (1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. Contingent Consideration for Acquisition Earn Outs Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations. The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. The fair value is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on the Company's internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 29, 2020: (in thousands) Fair Value Valuation Technique Unobservable Input Range Revenue based payments $ 23,926 Discounted cash flow Discount rate 4% - 5% Probability of payment 66% - 100% Projected fiscal year of payment 2023 - 2029 Technical milestones $ 3,368 Estimated probability Estimated probability 90% Projected year of payment 2020 - 2022 Total $ 27,294

Leases Leases

Leases Leases	9 Months Ended
	Feb. 29, 2020
Leases [Abstract]
Leases	LEASES Adoption of ASU No. 2016-02, Leases (Topic 842) On June 1, 2019, the Company adopted ASU No. 2016-02 using the modified retrospective approach. This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Comparative periods prior to adoption have not been retrospectively adjusted. The Company elected the three practical expedients that permit an entity to a) not reassess whether expired or existing contracts contain leases, b) not reassess lease classification for existing or expired leases, and c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. Further, the Company has elected to not recognize leases with terms of 12 months or less on the balance sheet, and elected to account for lease and non-lease components as a single component for certain classes of assets. The adoption of this standard resulted in the recording of an additional lease asset and lease liability of approximately $5.6 million. The standard did not have a material impact on the Company's Consolidated Statement of Operations, Stockholders Equity or Cash Flows. Leases The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The following table presents supplemental balance sheet information related to leases: (in thousands) Balance Sheet Location Feb 29, 2020 Assets Operating lease ROU asset Other assets $ 9,628 Liabilities Current operating lease liabilities Other current liabilities 1,879 Non-current operating lease liabilities Other long-term liabilities 7,724 Total lease liabilities $ 9,603 The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate: Feb 29, 2020 Weighted average remaining term (in years) 5.31 Weighted average discount rate 4.2 % The following table presents the maturities of the lease liabilities: (in thousands) Feb 29, 2020 Remainder of 2020 $ 563 2021 2,190 2022 2,073 2023 2,110 2024 1,562 2025 and thereafter 2,190 Total lease payments $ 10,688 Less: Imputed Interest 1,085 Total lease obligations $ 9,603 Less: Current portion of lease obligations 1,879 Long-term lease obligations $ 7,724 Included in the total lease obligations is a 7-year building operating lease with undiscounted payment obligations of $6.4 million that commenced during the third quarter of fiscal year 2020. In addition to the total lease obligations presented in the table above, the Company has a 5-year building operating lease with undiscounted payment obligations of $1.5 million that is expected to commence during fiscal year 2020. During the three and nine months ended February 29, 2020, the Company recognized $0.9 million and $2.5 million of operating lease expense, respectively, which includes immaterial short-term leases. As of February 29, 2020, the expenses on the Consolidated Statement of Operations were classified as follows: (in thousands) Three Months Ended Nine Months Ended Cost of sales $ 297 $ 856 Research and development 192 388 Sales and marketing 100 298 General and administrative 336 927 $ 925 $ 2,469 Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows: (in thousands) May 31, 2019 2020 $ 2,920 2021 2,338 2022 2,133 2023 2,131 2024 and thereafter 3,227 Total lease payments $ 12,749 The following table presents supplemental cash flow and other information related to leases for the nine months ended: (in thousands) Feb 29, 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,767 ROU assets obtained in exchange for lease liabilities Operating leases 5,595

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Feb. 29, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Legal Proceedings The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation. C.R. Bard, Inc. v. AngioDynamics, Inc. On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard’s complaint sought unspecified damages and other relief. The Company filed petitions for reexamination in the US Patent and Trademark Office ("USPTO") seeking to invalidate all three patents asserted by Bard in the litigation. The Company's petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the USPTO Board of Appeals and Interferences for all three reexaminations which were decided as follows: For US Patent No. 7,785,302, the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. For U.S. Patent No. 7,959,615 the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third, for U.S. Patent No. 7,947,022 the rejections of all twenty claims under reexamination were affirmed. Thereafter, Bard sought Rehearing in all three appeals and the Company sought Rehearing in the ‘302 and ‘615 appeals. The PTO denied all three Rehearing Requests, but modified its characterization of one prior art reference for the ‘302 and ‘022 decisions. Bard filed appeals to the Federal Circuit Court of Appeals in all three reexams and the Company Cross-Appealed for the ‘302 and the ‘615 reexams. MedComp also filed an Amicus Brief in support of the Company on November 22, 2017. Meanwhile, on July 12, 2017 Bard assigned the asserted patents to Bard Peripheral Vascular, Inc. (“BPV”) which was added as co-Appellant before the Federal Circuit and as a co-Plaintiff in the Utah action. An oral hearing was held on September 5, 2018 and the Court rendered its decision on September 28, 2018, affirming that claims 1-5 and 10 of the ‘615 patent were invalid, but that claims 6-7 of the 615 patent and claims 1-4 of the 302 patent were valid over the prior art references considered in the Reexamination proceedings. The Federal Circuit also reversed the PTAB’s claim construction ruling and remanded for consideration of obviousness for the remaining claims under the new claim construction ruling and for further findings with respect to whether one of the asserted references qualified as a printed publication. On January 28, 2019, on remand, the USPTO reversed the rejections of the ‘302 claims 1-10, ‘022 claims 1-20 and ‘615 claims 8-9. The USPTO has since issued Inter Partes Reexamination Certificates for the ‘302 Patent for the ‘022 patent and for the ‘615 patent. The Company thereafter filed a Motion to Unstay the Utah Case and that motion was granted. On November 4, 2019 the Court held a joint Status Conference among the Company’s Utah Action and two other cases filed by Bard on the same patents against MedComp and Smiths. The Court set a schedule for defendant's Motions to Dismiss or Transfer. The Company filed its motion on November 25, 2019; and Bard filed a responsive brief and a motion for venue discovery on December 9, 2019. The Company filed a responsive brief on December 16, 2019 and Bard filed a reply on December 23, 2019. On February 27, 2020, the Court referred all non-dispositive motions to Magistrate Furse and on March 3, 2020 the Court granted Bard’s Motion for Venue Discovery and denied the Company’s transfer motion without prejudice to re-filing after completion of the venue discovery, but no later than June 30, 2020. The parties have since stipulated to a schedule for completing venue discovery. The Company believes these claims are without merit and intends to defend them vigorously. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. On March 10, 2015, Bard and BPV filed suit in the United States District Court for the District of Delaware (the “Delaware Action") claiming certain of the Company's implantable port products infringe on three other U.S. patents held by Bard, which are different from those asserted in the Utah action. Bard's complaint seeks unspecified damages and other relief. On June 1, 2015, the Company filed two motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court. On January 12, 2016, the Court issued a decision denying both motions. A Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. On May 19, 2017, Bard served its Final Infringement Contentions and on June 2, 2017, the Company served its Final Invalidity Contentions. On October 20, 2017, the scheduling order for the case was amended to, among other things, set a trial date commencing July 23, 2018. The parties completed Expert Discovery in January 2018 and completed briefing on their respective case dispositive motions on April 27, 2018. On June 26, 2018, the Court denied all case dispositive motions, ruling that issues of material fact remained in dispute. On July 9, 2018, the Court continued the trial until March 2019. On January 9, 2019 the Court held a further claim construction hearing to resolve two outstanding claim construction issues prior to trial. A Report and Recommendation (by Magistrate-Judge Fallon) was issued on February 11, 2019 and entered by the Court on February 28, 2019. Jury selection was held on Friday March 1, 2019 and trial began on March 4, 2019. On day four of the jury trial, at the close of C.R. Bard’s case, the Court granted the Company's oral motion for judgment as a matter of law under rule 50(a) as well as its motions for summary judgement on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed. On April 5, 2019, Bard filed a precautionary Notice of Appeal to the Federal Circuit. On April 26, 2019, the District Court issued a Memorandum and Order confirming the grant of judgment in the Company’s favor of patent ineligibility, non-infringement, patent invalidity and no willful infringement. Meanwhile, on May 10, 2019, the Company filed a Motion for Attorney fees and non-taxable expenses under 35 USC Sec. 285. On May 21, 2019, the Court issued a Memorandum and Order which, inter alia, stayed proceedings on the Company’s fee Motion and the Company’s equitable claims pending appeal; and entered Final Judgment on May 21, 2019 as well. Bard filed a second Notice of Appeal on May 23, 2019. Both appeals have since been consolidated and Bard’s opening brief was filed on September 27, 2019; the Company's answering brief was filed on January 15, 2020; and Bard’s reply brief was filed on March 4, 2020. A hearing date has not yet been scheduled. The Company maintains its belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. AngioDynamics, Inc. v. C.R. Bard, Inc. On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”). In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs. The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs. The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard’s motion in its entirety. Discovery is largely complete, and the case is currently proceeding to summary judgment and trial. Merz North America Settlement On May 16, 2019, Merz North America, Inc. (“Merz”) commenced an action in the United States District Court for the Southern District of New York entitled Merz North America, Inc. v. AngioDynamics, Inc. In this action, Merz alleged breach of contract against AngioDynamics based on a March 1, 2016 Distribution Agreement. On June 28, 2019, AngioDynamics

Acquisition, Restructuring and

Acquisition, Restructuring and Other Items, Net	9 Months Ended
	Feb. 29, 2020
Restructuring and Related Activities [Abstract]
Acquisition, Restructuring and Other Items, Net	ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET Acquisition, Restructuring and Other Items For the three and nine months ended February 29, 2020 and February 28, 2019 acquisition, restructuring and other items, net consisted of: Three months ended Nine months ended (in thousands) Feb 29, 2020 Feb 28, 2019 Feb 29, 2020 Feb 28, 2019 Legal (1) $ 637 $ 1,778 $ 1,989 $ 5,524 Mergers and acquisitions (2) 154 292 782 3,153 Transition service agreement (3) (386) — (1,720) — Divestiture (4) 781 — 2,241 — Restructuring — 10 26 266 Other 379 470 1,168 757 Total $ 1,565 $ 2,550 $ 4,486 $ 9,700 (1) Legal expenses related to litigation that is outside the normal course of business. (2) Mergers and acquisitions expenses related to investment banking, legal and due diligence. (3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business. (4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY. Included in the $2.0 million in legal for the nine months ended February 29, 2020 is a $0.4 million settlement received for the Biolitec bankruptcy litigation. The settlement received offsets legal expenses paid related to the settlement proceedings. Restructuring The Company evaluates its performance and looks for opportunities to improve the overall operations of the Company on an ongoing basis. As a result of this evaluation, certain restructuring initiatives are taken to enhance the Company’s overall operations. Operational Consolidation

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Feb. 29, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	ACCUMULATED OTHER COMPREHENSIVE LOSS Changes in each component of accumulated other comprehensive loss, net of tax, are as follows for the three and nine months ended February 29, 2020: Three months ended Feb 29, 2020 (in thousands) Foreign currency translation loss Balance at November 30, 2019 $ (1,272) Other comprehensive income before reclassifications, net of tax 8 Amounts reclassified from accumulated other comprehensive loss — Net other comprehensive income $ 8 Balance at February 29, 2020 $ (1,264) Nine months ended Feb 29, 2020 (in thousands) Foreign currency translation loss Balance at May 31, 2019 $ (1,352) Other comprehensive income before reclassifications, net of tax 88 Amounts reclassified from accumulated other comprehensive loss — Net other comprehensive income $ 88 Balance at February 29, 2020 $ (1,264)

Recently Issued Accounting Pr_2

Recently Issued Accounting Pronouncements (Policies)	9 Months Ended
	Feb. 29, 2020
Accounting Changes and Error Corrections [Abstract]
Revenue from Contracts with Customers	Revenue RecognitionUnder ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Revenue Recognition Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract. In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer. The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability. Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations. Costs to Obtain or Fulfill a Customer Contract Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements: Recently Issued Accounting Pronouncements - Adopted Standard Description Date Adopted Effect on the Consolidated Financial Statements ASU 2016-02, Leases (Topic 842) This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. June 1, 2019 Refer to Note 14, Leases, for the required disclosures related to adopting this standard. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2018-13, Fair Value Measurement (Topic 820) This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes. June 1, 2020 The Company is currently assessing the impact of this standard on the consolidated financial statements. ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. June 1, 2020 The Company is currently assessing the impact of this standard on the consolidated financial statements.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Feb. 29, 2020
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the preliminary aggregate purchase price allocated to the net assets acquired: (in thousands) Preliminary allocation Adjustments (1) Revised allocation Accounts receivable $ 50 $ — $ 50 Inventory 150 — 150 Prepaid and other current assets 54 — 54 Long-term deposits 51 51 Property, plant and equipment 397 — 397 Intangible assets: Product technology 59,000 1,300 60,300 Goodwill 12,428 (1,001) 11,427 Total assets acquired $ 72,130 $ 299 $ 72,429 Liabilities assumed Accounts payable $ 84 $ — $ 84 Other current liabilities 615 — 615 Deferred tax liabilities 10,771 299 11,070 Total liabilities assumed $ 11,470 $ 299 $ 11,769 Net assets acquired $ 60,660 $ — $ 60,660 (1) Measurement period adjustments are recognized on a prospective basis in the period of change, instead of restating prior periods. There was no impact to reported earnings in connection with these measurement period adjustments for the periods presented. Amounts represent adjustments to the preliminary purchase price allocation first presented in the Company's Quarterly Report on Form 10-Q for the quarter ended November 30, 2019 resulting from revising the Company's purchase price allocation for this acquisition. (in thousands) Final allocation Accounts receivable $ 900 Inventory 732 Prepaid and other current assets 98 Property, plant and equipment 133 Intangible assets: RadiaDyne trademark 400 OARtrac trademark 200 RadiaDyne legacy product technology 1,500 OARtrac product technology 18,900 RadiaDyne customer relationships 4,600 Goodwill 47,982 Total assets acquired $ 75,445 Liabilities assumed Accounts payable $ 352 Accrued expenses 106 Total liabilities assumed $ 458 Net assets acquired $ 74,987 (in thousands) Final allocation Inventory $ 50 Property, plant and equipment 10 Intangible assets: BioSentry trademark 2,500 BioSentry product technology 20,900 Customer relationships 2,600 Goodwill 13,740 Net assets acquired $ 39,800

Divestitures (Tables)

Divestitures (Tables)	9 Months Ended
	Feb. 29, 2020
Discontinued Operations and Disposal Groups [Abstract]
Results of Discontinued Operations	The following table summarizes the financial results of our discontinued operations: Three Months Ended Nine Months Ended (in thousands) Feb 28, 2019 Feb 28, 2019 Net sales $ 20,818 $ 63,733 Cost of sales (exclusive of amortization) 12,290 38,134 Gross profit 8,528 25,599 Operating expenses Research and development 295 870 Sales and marketing 1,028 3,061 General and administrative 62 198 Amortization of intangibles 682 2,047 Total operating expenses 2,067 6,176 Operating income 6,461 19,423 Income from discontinued operations before income taxes 6,461 19,423 Income tax expense 1,056 3,057 Income from discontinued operations $ 5,405 $ 16,366 Total operating and investing cash flows of discontinued operations for the nine months ended February 28, 2019 is comprised of the following, which excludes the effect of income taxes: Nine Months Ended (in thousands) Feb 28, 2019 Net cash provided by operating activities 841 Net cash provided by investing activities 759

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Feb. 29, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the three and nine months ended February 29, 2020 and February 28, 2019: Three months ended Feb 29, 2020 Three months Ended Feb 28, 2019 (in thousands) United States International Total United States International Total Net sales Vascular Interventions & Therapies $ 26,788 $ 3,764 $ 30,552 $ 26,294 $ 3,004 $ 29,298 Vascular Access 20,018 4,624 24,642 18,952 3,396 $ 22,348 Oncology 8,083 6,503 14,586 8,154 5,724 $ 13,878 Total $ 54,889 $ 14,891 $ 69,780 $ 53,400 $ 12,124 $ 65,524 Nine months ended Feb 29, 2020 Nine months Ended Feb 28, 2019 (in thousands) United States International Total United States International Total Net sales Vascular Interventions & Therapies $ 80,065 $ 10,551 $ 90,616 $ 79,386 $ 9,484 $ 88,870 Vascular Access 57,865 12,720 70,585 59,480 10,381 69,861 Oncology 25,451 19,173 44,624 22,329 18,391 40,720 Total $ 163,381 $ 42,444 $ 205,825 $ 161,195 $ 38,256 $ 199,451
Contract Balances with Customers	The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers: (in thousands) Feb 29, 2020 May 31, 2019 Receivables $ 35,619 $ 43,577 Contract assets $ — $ — Contract liabilities $ 612 $ 681

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Feb. 29, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following: (in thousands) Feb 29, 2020 May 31, 2019 Raw materials $ 21,304 $ 16,045 Work in process 9,385 6,786 Finished goods 24,209 17,240 Inventories $ 54,898 $ 40,071

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Feb. 29, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Goodwill	The changes in the carrying amount of goodwill for the nine months ended February 29, 2020 were as follows: (in thousands) Goodwill balance at May 31, 2019 $ 347,666 Addition for Eximo acquisition (Note 2) 11,427 Goodwill balance at February 29, 2020 $ 359,093
Intangible Assets	Intangible assets consisted of the following: Feb 29, 2020 (in thousands) Gross carrying value Accumulated Net carrying Product technologies $ 251,773 $ (85,105) $ 166,668 Customer relationships 60,149 (29,005) 31,144 Trademarks 10,150 (6,640) 3,510 Licenses 6,087 (5,453) 634 $ 328,159 $ (126,203) $ 201,956 May 31, 2019 (in thousands) Gross carrying value Accumulated Net carrying Product technologies $ 182,971 $ (75,412) $ 107,559 Customer relationships 60,166 (25,950) 34,216 Trademarks 9,300 (6,404) 2,896 Licenses 5,752 (5,036) 716 $ 258,189 $ (112,802) $ 145,387
Schedule of Future Amortization Expense	Expected future amortization expense related to the intangible assets is as follows: (in thousands) Remainder of 2020 $ 4,856 2021 18,607 2022 18,003 2023 17,941 2024 16,367 2025 and thereafter 126,182 $ 201,956

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Feb. 29, 2020
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued liabilities consisted of the following: (in thousands) Feb 29, 2020 May 31, 2019 Payroll and related expenses $ 11,159 $ 14,987 Royalties 2,015 2,088 Accrued severance 1,020 504 Sales and franchise taxes 631 807 Outside services 2,347 3,514 Litigation matters — 2,700 Indemnification holdback 4,986 4,807 Other 5,287 8,931 $ 27,445 $ 38,338

Long Term Debt (Tables)

Long Term Debt (Tables)	9 Months Ended
	Feb. 29, 2020
Debt Disclosure [Abstract]
Schedule of Principal Obligations	The Company's maturities of principal obligations under the Credit Agreement are as follows as of February 29, 2020: (in thousands) Revolving Facility (1) $ 15,000 Less: Unamortized debt issuance costs (659) Total $ 14,341 (1) The Revolving Facility is due in fiscal year 2024.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Feb. 29, 2020
Earnings Per Share [Abstract]
Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding	The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 29, 2020 and February 28, 2019 (in thousands): Three Months Ended Nine Months Ended (in thousands) Feb 29, 2020 Feb 28, 2019 Feb 29, 2020 Feb 28, 2019 Basic 37,999 37,518 37,924 37,446 Effect of dilutive securities — — — — Diluted 37,999 37,518 37,924 37,446 Securities excluded as their inclusion would be anti-dilutive 2,699 2,293 2,656 2,293

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	9 Months Ended
	Feb. 29, 2020
Segment Reporting [Abstract]
Summary of Net Sales by Product Category	The table below summarizes net sales by Global Business Unit: Three Months Ended Nine months ended (in thousands) Feb 29, 2020 Feb 28, 2019 Feb 29, 2020 Feb 28, 2019 Net sales Vascular Interventions & Therapies $ 30,552 $ 29,298 $ 90,616 $ 88,870 Vascular Access 24,642 22,348 70,585 69,861 Oncology 14,586 13,878 44,624 40,720 Total $ 69,780 $ 65,524 $ 205,825 $ 199,451
Summary of Net Sales by Geographic Area	The table below presents net sales by geographic area based on external customer location: Three Months Ended Nine months ended (in thousands) Feb 29, 2020 Feb 28, 2019 Feb 29, 2020 Feb 28, 2019 Net sales United States $ 54,889 $ 53,400 $ 163,381 $ 161,195 International 14,891 12,124 42,444 38,256 Total $ 69,780 $ 65,524 $ 205,825 $ 199,451

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Feb. 29, 2020
Fair Value Disclosures [Abstract]
Fair Value of Assets and Liabilities Measured on a Recurring Basis	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 29, 2020 and May 31, 2019: Fair Value Measurements using inputs considered as: Fair Value at Feb 29, 2020 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 27,294 $ 27,294 Total Financial Liabilities $ — $ — $ 27,294 $ 27,294 Fair Value Measurements using inputs considered as: Fair Value at May 31, 2019 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 13,486 $ 13,486 Total Financial Liabilities $ — $ — $ 13,486 $ 13,486
Fair Value Measurements Using Significant Unobservable Inputs	The table below presents the changes in fair value components of Level 3 instruments in the three and nine months ended February 29, 2020: Three Months Ended Feb 29, 2020 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, November 30, 2019 $ 26,875 Total gains or losses (realized/unrealized): Change in present value of contingent consideration (1) 419 Balance, February 29, 2020 $ 27,294 Nine Months Ended Feb 29, 2020 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, May 31, 2019 $ 13,486 Total gains or losses (realized/unrealized): Contingent consideration liability recorded as the result of the acquisitions (Note 2) 14,900 Change in present value of contingent consideration (1) 116 Contingent consideration payments (1,208) Balance, February 29, 2020 $ 27,294
Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability	The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 29, 2020: (in thousands) Fair Value Valuation Technique Unobservable Input Range Revenue based payments $ 23,926 Discounted cash flow Discount rate 4% - 5% Probability of payment 66% - 100% Projected fiscal year of payment 2023 - 2029 Technical milestones $ 3,368 Estimated probability Estimated probability 90% Projected year of payment 2020 - 2022 Total $ 27,294

Leases (Tables)

Leases (Tables)	9 Months Ended
	Feb. 29, 2020
Leases [Abstract]
Supplemental balance sheet information	The following table presents supplemental balance sheet information related to leases: (in thousands) Balance Sheet Location Feb 29, 2020 Assets Operating lease ROU asset Other assets $ 9,628 Liabilities Current operating lease liabilities Other current liabilities 1,879 Non-current operating lease liabilities Other long-term liabilities 7,724 Total lease liabilities $ 9,603 Feb 29, 2020 Weighted average remaining term (in years) 5.31 Weighted average discount rate 4.2 %
Lease liability schedule	The following table presents the maturities of the lease liabilities: (in thousands) Feb 29, 2020 Remainder of 2020 $ 563 2021 2,190 2022 2,073 2023 2,110 2024 1,562 2025 and thereafter 2,190 Total lease payments $ 10,688 Less: Imputed Interest 1,085 Total lease obligations $ 9,603 Less: Current portion of lease obligations 1,879 Long-term lease obligations $ 7,724
Lease liability schedule as of prior year end	Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows: (in thousands) May 31, 2019 2020 $ 2,920 2021 2,338 2022 2,133 2023 2,131 2024 and thereafter 3,227 Total lease payments $ 12,749
Supplemental cash flow information	As of February 29, 2020, the expenses on the Consolidated Statement of Operations were classified as follows: (in thousands) Three Months Ended Nine Months Ended Cost of sales $ 297 $ 856 Research and development 192 388 Sales and marketing 100 298 General and administrative 336 927 $ 925 $ 2,469 The following table presents supplemental cash flow and other information related to leases for the nine months ended: (in thousands) Feb 29, 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,767 ROU assets obtained in exchange for lease liabilities Operating leases 5,595

Acquisition, Restructuring an_2

Acquisition, Restructuring and Other Items, Net (Tables)	9 Months Ended
	Feb. 29, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	For the three and nine months ended February 29, 2020 and February 28, 2019 acquisition, restructuring and other items, net consisted of: Three months ended Nine months ended (in thousands) Feb 29, 2020 Feb 28, 2019 Feb 29, 2020 Feb 28, 2019 Legal (1) $ 637 $ 1,778 $ 1,989 $ 5,524 Mergers and acquisitions (2) 154 292 782 3,153 Transition service agreement (3) (386) — (1,720) — Divestiture (4) 781 — 2,241 — Restructuring — 10 26 266 Other 379 470 1,168 757 Total $ 1,565 $ 2,550 $ 4,486 $ 9,700 (1) Legal expenses related to litigation that is outside the normal course of business. (2) Mergers and acquisitions expenses related to investment banking, legal and due diligence. (3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Feb. 29, 2020
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in each component of accumulated other comprehensive loss, net of tax, are as follows for the three and nine months ended February 29, 2020: Three months ended Feb 29, 2020 (in thousands) Foreign currency translation loss Balance at November 30, 2019 $ (1,272) Other comprehensive income before reclassifications, net of tax 8 Amounts reclassified from accumulated other comprehensive loss — Net other comprehensive income $ 8 Balance at February 29, 2020 $ (1,264) Nine months ended Feb 29, 2020 (in thousands) Foreign currency translation loss Balance at May 31, 2019 $ (1,352) Other comprehensive income before reclassifications, net of tax 88 Amounts reclassified from accumulated other comprehensive loss — Net other comprehensive income $ 88 Balance at February 29, 2020 $ (1,264)

Recently Issued Accounting Pr_3

Recently Issued Accounting Pronouncements (Tables)	9 Months Ended
	Feb. 29, 2020
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements: Recently Issued Accounting Pronouncements - Adopted Standard Description Date Adopted Effect on the Consolidated Financial Statements ASU 2016-02, Leases (Topic 842) This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. June 1, 2019 Refer to Note 14, Leases, for the required disclosures related to adopting this standard. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2018-13, Fair Value Measurement (Topic 820) This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes. June 1, 2020 The Company is currently assessing the impact of this standard on the consolidated financial statements. ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. June 1, 2020 The Company is currently assessing the impact of this standard on the consolidated financial statements.

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ in Thousands	Dec. 17, 2019	Oct. 02, 2019	Sep. 21, 2018	Aug. 14, 2018	Aug. 31, 2019	Feb. 29, 2020	Nov. 30, 2019	May 31, 2019
Business Acquisition [Line Items]
Contingent consideration, liabilities						$ 27,294		$ 13,486
Other long-term liabilities						8,015		521
Accrued liabilities						$ 27,445		38,338
C3 Wave Tip Location Asset
Business Acquisition [Line Items]
Aggregate purchase price	$ 10,000
Contingent consideration for acquisition earn outs	5,000
Inventory	$ 600
Useful life (years)	15 years
Trademark | C3 Wave Tip Location Asset
Business Acquisition [Line Items]
Finite-lived intangibles	$ 900
Product technology | C3 Wave Tip Location Asset
Business Acquisition [Line Items]
Finite-lived intangibles	$ 8,500
Minimum
Business Acquisition [Line Items]
Useful life (years)						2 years
Maximum
Business Acquisition [Line Items]
Useful life (years)						18 years
Eximo Medical, Ltd.
Business Acquisition [Line Items]
Aggregate purchase price		$ 60,700
Payments to acquire business		45,800
Contingent consideration, liabilities		$ 14,900
Inventory						$ 150	$ 150
Eximo Medical, Ltd. | Product technology
Business Acquisition [Line Items]
Useful life (years)						15 years
Intangible assets						$ 60,300	$ 59,000
RadiaDyne
Business Acquisition [Line Items]
Aggregate purchase price			$ 75,000
Payments to acquire business			47,900
Contingent consideration, liabilities			22,300
Acquisition related costs					$ 1,600	600
Inventory								732
Other long-term liabilities			4,600			$ 4,600
Accrued liabilities			$ 200
RadiaDyne | Customer relationships
Business Acquisition [Line Items]
Useful life (years)			15 years
Intangible assets								4,600
RadiaDyne | Minimum | Trademark
Business Acquisition [Line Items]
Useful life (years)			5 years
RadiaDyne | Minimum | Product technology
Business Acquisition [Line Items]
Useful life (years)			7 years
RadiaDyne | Maximum | Trademark
Business Acquisition [Line Items]
Useful life (years)			7 years
RadiaDyne | Maximum | Product technology
Business Acquisition [Line Items]
Useful life (years)			10 years
RadiaDyne | Revenue milestones
Business Acquisition [Line Items]
Contingent consideration, liabilities			$ 16,500
RadiaDyne | Technical milestones
Business Acquisition [Line Items]
Contingent consideration, liabilities			$ 5,800
BioSentry
Business Acquisition [Line Items]
Aggregate purchase price				$ 39,800
Payments to acquire business				37,000
Contingent consideration, liabilities				$ 2,800
Acquisition related costs					$ 1,000
Inventory								50
BioSentry | Trademark
Business Acquisition [Line Items]
Useful life (years)				15 years
Intangible assets								2,500
BioSentry | Product technology
Business Acquisition [Line Items]
Useful life (years)				15 years
Intangible assets								20,900
BioSentry | Customer relationships
Business Acquisition [Line Items]
Useful life (years)				10 years
Intangible assets								$ 2,600

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended
	Feb. 29, 2020	Nov. 30, 2019	May 31, 2019
Assets acquired
Goodwill	$ 359,093		$ 347,666
Eximo Medical, Ltd.
Assets acquired
Receivables	50	$ 50
Inventory	150	150
Prepaid and other current assets	54	54
Long-term deposits	51	51
Property, plant and equipment	397	397
Goodwill	11,427	12,428
Goodwill, adjustments	(1,001)
Total assets acquired	72,429	72,130
Total assets acquired, adjustments	299
Liabilities assumed
Accounts payable	84	84
Other current liabilities	615	615
Deferred tax liabilities	11,070	10,771
Deferred tax liabilities, adjustments	299
Total liabilities assumed	11,769	11,470
Total liabilities assumed, adjustments	299
Net assets acquired	60,660	60,660
Net assets acquired, adjustments	0
Eximo Medical, Ltd. | Product technology
Assets acquired
Intangible assets	60,300	$ 59,000
Intangible assets, adjustments	$ 1,300
RadiaDyne
Assets acquired
Receivables			900
Inventory			732
Prepaid and other current assets			98
Property, plant and equipment			133
Goodwill			47,982
Total assets acquired			75,445
Liabilities assumed
Accounts payable			352
Accrued expenses			106
Total liabilities assumed			458
Net assets acquired			74,987
RadiaDyne | RadiaDyne trademark
Assets acquired
Intangible assets			400
RadiaDyne | OarTrac trademark
Assets acquired
Intangible assets			200
RadiaDyne | RadiaDyne legacy product technology
Assets acquired
Intangible assets			1,500
RadiaDyne | OarTrac product technology
Assets acquired
Intangible assets			18,900
RadiaDyne | Customer relationships
Assets acquired
Intangible assets			4,600
BioSentry
Assets acquired
Inventory			50
Property, plant and equipment			10
Goodwill			13,740
Liabilities assumed
Net assets acquired			39,800
BioSentry | Trademark
Assets acquired
Intangible assets			2,500
BioSentry | Product technology
Assets acquired
Intangible assets			20,900
BioSentry | Customer relationships
Assets acquired
Intangible assets			$ 2,600

Divestitures (Details)

Divestitures (Details) - USD ($) $ in Millions	3 Months Ended
	Aug. 31, 2019	May 31, 2019
NAMIC Fluid Management Business | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received		$ 169.2
Gain on divestiture	$ 46.6
Working capital adjustments	$ 0.6
Medline
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Service period duration (months)	24 months

Divestitures - Results of Disco

Divestitures - Results of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations	$ 0	$ 5,405	$ 0	$ 16,366
NAMIC Fluid Management Business | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	20,818		63,733
Cost of sales (exclusive of amortization)	12,290		38,134
Gross profit	8,528		25,599
Research and development	295		870
Sales and marketing	1,028		3,061
General and administrative	62		198
Amortization of intangibles	682		2,047
Total operating expenses	2,067		6,176
Operating income	6,461		19,423
Income from discontinued operations before income taxes	6,461		19,423
Income tax expense	1,056		3,057
Income from discontinued operations	5,405		$ 16,366
Net cash provided by operating activities	841
Net cash provided by investing activities	$ 759

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 69,780	$ 65,524	$ 205,825	$ 199,451
United States
Disaggregation of Revenue [Line Items]
Net sales	54,889	53,400	163,381	161,195
International
Disaggregation of Revenue [Line Items]
Net sales	14,891	12,124	42,444	38,256
Vascular Interventions & Therapies
Disaggregation of Revenue [Line Items]
Net sales	30,552	29,298	90,616	88,870
Vascular Interventions & Therapies  | United States
Disaggregation of Revenue [Line Items]
Net sales	26,788	26,294	80,065	79,386
Vascular Interventions & Therapies  | International
Disaggregation of Revenue [Line Items]
Net sales	3,764	3,004	10,551	9,484
Vascular Access
Disaggregation of Revenue [Line Items]
Net sales	24,642	22,348	70,585	69,861
Vascular Access | United States
Disaggregation of Revenue [Line Items]
Net sales	20,018	18,952	57,865	59,480
Vascular Access | International
Disaggregation of Revenue [Line Items]
Net sales	4,624	3,396	12,720	10,381
Oncology
Disaggregation of Revenue [Line Items]
Net sales	14,586	13,878	44,624	40,720
Oncology | United States
Disaggregation of Revenue [Line Items]
Net sales	8,083	8,154	25,451	22,329
Oncology | International
Disaggregation of Revenue [Line Items]
Net sales	$ 6,503	$ 5,724	$ 19,173	$ 18,391

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Narrative (Details) $ in Millions	9 Months Ended
	Feb. 29, 2020USD ($)
Disaggregation of Revenue [Line Items]
Days after purchase after which pre-approval is required for product return	30 days
Restocking charge (as percent)	20.00%
Minimum remaining period prior to product expiration	12 months
Revenue recognized from contract liability balances in respective periods	$ 1.6
Additions to contract liabilities	$ 1.6
Minimum
Disaggregation of Revenue [Line Items]
Payment term	30 days
Maximum
Disaggregation of Revenue [Line Items]
Payment term	90 days

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Contract Balances with Customers (Details) - USD ($) $ in Thousands	Feb. 29, 2020	May 31, 2019
Revenue from Contract with Customer [Abstract]
Receivables	$ 35,619	$ 43,577
Contract assets	0	0
Contract liabilities	$ 612	$ 681

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Feb. 29, 2020	May 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 21,304	$ 16,045
Work in process	9,385	6,786
Finished goods	24,209	17,240
Inventories	$ 54,898	$ 40,071

Inventories - Narrative (Detail

Inventories - Narrative (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Feb. 29, 2020	May 31, 2019
Inventory [Line Items]
Inventory valuation reserves	$ 4,000	$ 4,200
Inventory write-down	700	700
Acculis Inventory
Inventory [Line Items]
Inventory valuation reserves	$ 300	$ 400

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Narrative (Detail)	Dec. 31, 2019USD ($)	Feb. 29, 2020USD ($)	Feb. 28, 2019USD ($)	Feb. 29, 2020USD ($)segment	Feb. 28, 2019USD ($)
Finite-Lived Intangible Assets [Line Items]
Number of reporting units | segment				1
Goodwill impairment	$ 0
Amortization of intangibles		$ 5,019,000	$ 4,660,000	$ 13,417,000	$ 12,599,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill				2 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill				18 years

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Goodwill Rollforward (Details) $ in Thousands	9 Months Ended
	Feb. 29, 2020USD ($)
Goodwill [Roll Forward]
Goodwill balance at May 31, 2019	$ 347,666
Addition for Eximo acquisition (Note 2)	11,427
Goodwill balance at February 29, 2020	$ 359,093

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	Feb. 29, 2020	May 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	$ 328,159	$ 258,189
Accumulated amortization	(126,203)	(112,802)
Net carrying value, finite intangible items	201,956	145,387
Product technologies
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	251,773	182,971
Accumulated amortization	(85,105)	(75,412)
Net carrying value, finite intangible items	166,668	107,559
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	60,149	60,166
Accumulated amortization	(29,005)	(25,950)
Net carrying value, finite intangible items	31,144	34,216
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	10,150	9,300
Accumulated amortization	(6,640)	(6,404)
Net carrying value, finite intangible items	3,510	2,896
Licenses
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	6,087	5,752
Accumulated amortization	(5,453)	(5,036)
Net carrying value, finite intangible items	$ 634	$ 716

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Expected Future Amortization Expense (Detail) - USD ($) $ in Thousands	Feb. 29, 2020	May 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2020	$ 4,856
2021	18,607
2022	18,003
2023	17,941
2024	16,367
2025 and thereafter	126,182
Net carrying value, finite intangible items	$ 201,956	$ 145,387

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Feb. 29, 2020	May 31, 2019
Other Liabilities Disclosure [Abstract]
Payroll and related expenses	$ 11,159	$ 14,987
Royalties	2,015	2,088
Accrued severance	1,020	504
Sales and franchise taxes	631	807
Outside services	2,347	3,514
Litigation matters	0	2,700
Indemnification holdback	4,986	4,807
Other	5,287	8,931
Total accrued liabilities	$ 27,445	$ 38,338

Long Term Debt - Narrative (Det

Long Term Debt - Narrative (Detail) - Credit Facility	9 Months Ended
	Feb. 29, 2020USD ($)covenant	Jun. 03, 2019USD ($)
Debt Instrument [Line Items]
Debt default interest rate increase (percentage)	2.00%
Maximum total leverage ratio	3
Maximum total leverage ratio subsequent to material acquisitions	3.50
Minimum fixed charge coverage ratio	1.25
Minimum
Debt Instrument [Line Items]
Commitment fee (percentage)	0.20%
Maximum
Debt Instrument [Line Items]
Commitment fee (percentage)	0.25%
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit		$ 125,000,000
Line of credit accordion feature		$ 75,000,000
Number of covenants | covenant	2
Borrowings outstanding	$ 15,000,000
Interest rate at period end (percentage)	2.92%
Less: Unamortized debt issuance costs	$ (659,000)
Total	$ 14,341,000
Revolving Credit Facility | Minimum | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percentage)	0.25%
Revolving Credit Facility | Minimum | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate (percentage)	1.25%
Revolving Credit Facility | Maximum | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percentage)	0.75%
Revolving Credit Facility | Maximum | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate (percentage)	1.75%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended
	Feb. 29, 2020	Feb. 28, 2019
Income Tax Disclosure [Abstract]
Estimated federal statutory income tax rate	12.90%	14.00%

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Detail) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Charges against income for share-based payment arrangements	$ 1.8	$ 2.4	$ 6	$ 7.1
Unrecognized compensation expenses related to share-based payment arrangements	$ 14		$ 14
Recognition period			4 years
The 2004 Plan and Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount of shares issuable through two stock-based compensation plans	11.3		11.3

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019
Earnings Per Share [Abstract]
Basic (shares)	37,999	37,518	37,924	37,446
Effect of dilutive securities (shares)	0	0	0	0
Diluted (shares)	37,999	37,518	37,924	37,446
Securities excluded as their inclusion would be anti-dilutive (shares)	2,699	2,293	2,656	2,293

Segment and Geographic Inform_3

Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019
Segment Reporting Information [Line Items]
Net sales	$ 69,780	$ 65,524	$ 205,825	$ 199,451
Vascular Interventions & Therapies
Segment Reporting Information [Line Items]
Net sales	30,552	29,298	90,616	88,870
Vascular Access
Segment Reporting Information [Line Items]
Net sales	24,642	22,348	70,585	69,861
Oncology
Segment Reporting Information [Line Items]
Net sales	$ 14,586	$ 13,878	$ 44,624	$ 40,720

Segment and Geographic Inform_4

Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 69,780	$ 65,524	$ 205,825	$ 199,451
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	54,889	53,400	163,381	161,195
International
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 14,891	$ 12,124	$ 42,444	$ 38,256

Fair Value - Fair Value of Asse

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) - USD ($) $ in Thousands	Feb. 29, 2020	May 31, 2019
Financial Liabilities
Contingent consideration for acquisition earn outs	$ 27,294	$ 13,486
Recurring
Financial Liabilities
Total Financial Liabilities	27,294	13,486
Level 1 | Recurring
Financial Liabilities
Contingent consideration for acquisition earn outs	0	0
Total Financial Liabilities	0	0
Level 2 | Recurring
Financial Liabilities
Contingent consideration for acquisition earn outs	0	0
Total Financial Liabilities	0	0
Level 3 | Recurring
Financial Liabilities
Contingent consideration for acquisition earn outs	27,294	13,486
Total Financial Liabilities	$ 27,294	$ 13,486

Fair Value - Fair Value Measure

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Feb. 29, 2020	Feb. 29, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Financial liabilities, begining balance	$ 26,875	$ 13,486
Contingent consideration liability recorded as the result of the acquisitions (Note 2)		14,900
Change in present value of contingent consideration	419	116
Contingent consideration payments		(1,208)
Financial liabilities, ending balance	$ 27,294	$ 27,294

Fair Value - Summary Showing th

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) $ in Thousands	Feb. 29, 2020USD ($)	May 31, 2019USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liabilities	$ 27,294	$ 13,486
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Financial Liabilities	27,294	13,486
Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liabilities	27,294	13,486
Total Financial Liabilities	27,294	$ 13,486
Revenue based payments | Discounted cash flow | Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liabilities	23,926
Technical milestones | Estimated probability | Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liabilities	$ 3,368
Contingent consideration, liability, measurement input	0.90
Minimum | Revenue based payments | Discount rate | Discounted cash flow | Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liability, measurement input	0.04
Minimum | Revenue based payments | Probability of payment | Discounted cash flow | Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liability, measurement input	0.66
Maximum | Revenue based payments | Discount rate | Discounted cash flow | Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liability, measurement input	0.05
Maximum | Revenue based payments | Probability of payment | Discounted cash flow | Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liability, measurement input	1
Contingent Consideration | Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Financial Liabilities	$ 27,294

Fair Value - Additional Informa

Fair Value - Additional Information (Detail) $ in Millions	Feb. 29, 2020USD ($)
Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Potential amount of undiscounted future contingent consideration	$ 34
Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Potential amount of undiscounted future contingent consideration	$ 54

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Feb. 29, 2020	Feb. 29, 2020	Jun. 01, 2019
Lessee, Lease, Description [Line Items]
Operating lease ROU asset	$ 9,628	$ 9,628
Total lease liabilities	9,603	9,603
Non-cash lease expense	$ 925	$ 2,469
Building | Seven Year Building Lease
Lessee, Lease, Description [Line Items]
Lease term (years)	7 years	7 years
Lease payments	$ 6,400	$ 6,400
Building | Two Year Building Lease
Lessee, Lease, Description [Line Items]
Lease term (years)	5 years	5 years
Lease payments	$ 1,500	$ 1,500
Accounting Standards Update 2016-02
Lessee, Lease, Description [Line Items]
Operating lease ROU asset			$ 5,600
Total lease liabilities			$ 5,600
Cost of sales
Lessee, Lease, Description [Line Items]
Non-cash lease expense	297	856
General and administrative
Lessee, Lease, Description [Line Items]
Non-cash lease expense	$ 336	$ 927

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) $ in Thousands	Feb. 29, 2020USD ($)
Leases [Abstract]
Operating lease ROU asset	$ 9,628
Less: Current portion of lease obligations	1,879
Long-term lease obligations	7,724
Total lease obligations	$ 9,603
Weighted average remaining term (in years)	5 years 3 months 21 days
Weighted average discount rate (percent)	4.20%

Leases - Liability Maturity Sch

Leases - Liability Maturity Schedule (Details) $ in Thousands	Feb. 29, 2020USD ($)
Leases [Abstract]
Remainder of 2020	$ 563
2021	2,190
2022	2,073
2023	2,110
2024	1,562
2025 and thereafter	2,190
Total lease payments	10,688
Less: Imputed Interest	1,085
Total lease obligations	9,603
Less: Current portion of lease obligations	1,879
Long-term lease obligations	$ 7,724

Leases - Supplemental Statement

Leases - Supplemental Statement of Operations Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Feb. 29, 2020	Feb. 29, 2020
Lessee, Lease, Description [Line Items]
Non-cash lease expense	$ 925	$ 2,469
Cost of sales
Lessee, Lease, Description [Line Items]
Non-cash lease expense	297	856
Research and development
Lessee, Lease, Description [Line Items]
Non-cash lease expense	192	388
Sales and marketing
Lessee, Lease, Description [Line Items]
Non-cash lease expense	100	298
General and administrative
Lessee, Lease, Description [Line Items]
Non-cash lease expense	$ 336	$ 927

Leases - Non-Cancelable Payment

Leases - Non-Cancelable Payments Schedule (Details) $ in Thousands	May 31, 2019USD ($)
Leases [Abstract]
2020	$ 2,920
2021	2,338
2022	2,133
2023	2,131
2024 and thereafter	3,227
Total lease payments	$ 12,749

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) $ in Thousands	9 Months Ended
	Feb. 29, 2020USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 1,767
Operating leases	$ 5,595

Commitments and Coontingencies

Commitments and Coontingencies - Additional Information (Detail)	Mar. 07, 2019patent	Mar. 29, 2016claim	Mar. 24, 2016claim	Mar. 11, 2016claim	Jun. 01, 2015motion	Jan. 11, 2012claimreexamination_appealPetition	Jan. 31, 2017reexamination_appeal	Feb. 29, 2020claim	Nov. 04, 2019claim
C.R. Bard, Inc.
Loss Contingencies [Line Items]
Number of petitions filed for reexamination of patents | Petition						3
The Utah Action
Loss Contingencies [Line Items]
Number of claims dismissed		20	8	6		40
Number of reexaminations | reexamination_appeal						3
Number of pending claims			10	10		41
Number of claims reversed			2	4
The Utah Action | C.R. Bard, Inc. | Pending Litigation
Loss Contingencies [Line Items]
Number of reexaminations | reexamination_appeal							3
Number of claims reversed | reexamination_appeal							3
MedComp and Smiths Patent Action | C.R. Bard, Inc.
Loss Contingencies [Line Items]
Number of pending claims									2
The Delaware Action
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon	3				2
Construction Issues
Loss Contingencies [Line Items]
Number of pending claims								2

Acquisition, Restructuring an_3

Acquisition, Restructuring and Other Items, Net - Summary (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 1,565	$ 2,550	$ 4,486	$ 9,700
Legal
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	637	1,778	1,989	5,524
Mergers and acquisitions
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	154	292	782	3,153
Transition service agreement
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	(386)	0	(1,720)	0
Divestiture
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	781	0	2,241	0
Restructuring
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	0	10	26	266
Other
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 379	$ 470	$ 1,168	$ 757

Acquisition, Restructuring an_4

Acquisition, Restructuring and Other Items, Net - Narrative (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 1,565	$ 2,550	$ 4,486	$ 9,700
Legal
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 637	$ 1,778	1,989	$ 5,524
Biolitec Bankruptcy
Restructuring Cost and Reserve [Line Items]
Proceeds from Legal Settlements			$ 400

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) - Schedule (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	9 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Nov. 30, 2019	Feb. 29, 2020	Feb. 28, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ 613,810	$ 549,563	$ 614,815	$ 614,815	$ 542,595
Other comprehensive income (loss), net of tax	8	173		88	(125)
Ending Balance	610,475	554,079	613,810	610,475	554,079
Accumulated other comprehensive income (loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(1,272)	(1,250)	(1,352)	(1,352)	(952)
Ending Balance	(1,264)	$ (1,077)	(1,272)	(1,264)	$ (1,077)
Foreign currency translation loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(1,272)		(1,352)	(1,352)
Other comprehensive income before reclassifications, net of tax	8		88
Amounts reclassified from accumulated other comprehensive loss	0		0
Other comprehensive income (loss), net of tax	8		88
Ending Balance	$ (1,264)		$ (1,272)	$ (1,264)